NCT03527589 - Embosphere® PROstate Post Market Study | Biotech Hunter

Enrollment

499

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

January 21, 2020

Study Completion Date

January 22, 2022

Conditions

Benign Prostatic HyperplasiaLower Urinary Tract Symptoms

Interventions

DEVICE

Prostate artery embolization

Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.

Trial Locations (15)

12100

Azienda Ospedaliera S. Croce e Carle Cuneo, Cuneo

20162

Ospedale Niguarda Ca' Granda, Milan

33136

University of Miami- Miller School of Medicine, Miami

33308

Holy Cross Hospital, Fort Lauderdale

63110

St. Louis University Hospital, St Louis

75015

Hôspital Européan Georges Pompidou HEGP, Paris

90095

Ronald Reagan UCLA Medical Center, Los Angeles

University of California Los Angeles, Los Angeles

90822

VA Long Beach Healthcare Systems, Long Beach

92868

UC Irvine Health, Orange

99204

Providence Sacred Heart, Spokane

OX3 7LE

Churchill Hospital, Headington

GU16 7UJ

Frimley Park Hospital, Camberley

BH7 7DW

Royal Bournemouth and Christchurch Hospital, Bournemouth

Unknown

Royal Berkshire Hospital, Reading